Jose Luis Pedraz obtained his Degree and doctorate in pharmacy from the University of Salamanca. He was a Professor at the University of Salamanca, until 1992, and has been a professor at the University of the Basque Country since 1992. Postdoctoral stay in the Department of Neonatal Pharmacology at the Mario Negri Institute in Milan in 1986. He completed my training in the R&D departments of multinational pharmaceutical companies such as UPJOHN and Merrell Down Research Institute in 1989. He is a principal researcher in the NanoBioCel group of the UPV/EHU, which is a Consolidated Group of Excellence type A of the Basque Government. Within CIBER BBN, he is the head and director of the medicine formulation laboratory that belongs to the singular scientific infrastructure (ICTS) Nanbiosis. Founder and director of the Pharmaceutical Development Unit of the Basque Country currently TECNALIA Pharma Labs integrated into the Tecnalia Corporation within a joint project with the UPV/EHU of which he is a scientific director. His research work focuses on the area of Drug Delivery, specifically on the design and development of particular microsystems, non-viral vectors for gene therapy, microencapsulation of cells for the development of bioartificial organs and scaffolds and 3d bioprinting techniques with applications in cell therapy and generative medicine.
Research Keywords & Expertise
Gene Therapy
Nanotechnology
Regenerative Medicine
Tissue Engineering
Fingerprints
10%
Gene Therapy
8%
Tissue Engineering
7%
Nanotechnology
5%
Regenerative Medicine
Short Biography
Jose Luis Pedraz obtained his Degree and doctorate in pharmacy from the University of Salamanca. He was a Professor at the University of Salamanca, until 1992, and has been a professor at the University of the Basque Country since 1992. Postdoctoral stay in the Department of Neonatal Pharmacology at the Mario Negri Institute in Milan in 1986. He completed my training in the R&D departments of multinational pharmaceutical companies such as UPJOHN and Merrell Down Research Institute in 1989. He is a principal researcher in the NanoBioCel group of the UPV/EHU, which is a Consolidated Group of Excellence type A of the Basque Government. Within CIBER BBN, he is the head and director of the medicine formulation laboratory that belongs to the singular scientific infrastructure (ICTS) Nanbiosis. Founder and director of the Pharmaceutical Development Unit of the Basque Country currently TECNALIA Pharma Labs integrated into the Tecnalia Corporation within a joint project with the UPV/EHU of which he is a scientific director. His research work focuses on the area of Drug Delivery, specifically on the design and development of particular microsystems, non-viral vectors for gene therapy, microencapsulation of cells for the development of bioartificial organs and scaffolds and 3d bioprinting techniques with applications in cell therapy and generative medicine.